SB 242784 | 201929-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: SB 242784
• 英文别名: (2Z,4E) N-(1,2,2,6,6-pentamethyl-piperidin-4-yl)5-(5,6-dichloro-1H-indol-2-yl)-2-methoxy-penta-2,4-dienamide；SB-242782；(2Z,4E)-5-(5,6-Dichloro-1H-indol-2-yl)-2-methoxy-N-(1,2,2,6,6-pentamethyl piperidin-4-yl)-2,4-pentadienamide；(2Z,4E)-5-(5,6-dichloro-1H-indol-2-yl)-2-methoxy-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)penta-2,4-dienamide
• CAS: 201929-00-2
• 化学式: C₂₄H₃₁Cl₂N₃O₂
• 分子量: 464.435
• InChiKey: NAQKKRDQKSXZSM-KQWKBXPTSA-N

物化性质

• 沸点：
  644.8±55.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  57.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  SB 242784 以 四氢呋喃 为溶剂， 反应 120.0h， 以21%的产率得到(2E,4E)-5-(5,6-Dichloro-1H-indol-2-yl)-2-methoxy-N-(1,2,2,6,6-pentamethyl Piperidin-4-yl)-2,4-pentadienamide
  参考文献：
  名称：

  (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase

  摘要：

  Optimisation of a novel series of osteoclast ATPase inhibitors led to (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-( 1,2,2,6,6-pentamethylpiperidin-4-yl)-2,4-pentadienamide (1) that was the most potent compound in an in vitro osteoclast ATPase assay and in human bone resorption assays. Two of the possible geometric isomers have also been prepared and shown to be significantly less potent than 1. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00660-x
• 作为产物：
  描述：

  3,4-二氯苯乙酸 在 lithium hydroxide 、 sodium hydroxide 、 copper(l) iodide 、 四(三苯基膦)钯 、 三氯化铝 、 氯化亚砜 、 chromium sulfate 、 硫酸 、 硝酸 、 铁粉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 146.0h， 生成 SB 242784
  参考文献：
  名称：

  合成破骨细胞抑制剂SB-242784

  摘要：

  破骨细胞抑制剂SB-242784（1）是由关键的吲哚中间体4制备的。有机锡2c与溴化丙烯酸酯11的“ Stille”交叉偶联提供了二烯12，它也是通过烯炔16的还原异构化过程获得的。溴酰胺3是由相应的酸制备7将其容易地从溴丙酮酸获得。

  DOI：

  10.1016/s0040-4039(03)00544-6

文献信息

• Synthesis of 2-dienylindole, SB 242784, by a three-component palladium-catalyzed coupling reaction
  作者：Marvin S. Yu、Lewilynn Lopez de Leon、Michael A. McGuire、Glen Botha

  DOI：10.1016/s0040-4039(98)02161-3

  日期：1998.12

  The synthesis of SB 242784 using a novel one-pot Castro-Stephens-Suzuki reaction as the key reaction is described.

  描述了使用新型一锅法Castro-Stephens-Suzuki反应作为关键反应合成SB 242784的方法。
• Indole derivatives for the treatment of osteoporosis
  申请人：Smith Kline Beecham SpA

  公开号：US20020173659A1

  公开（公告）日：2002-11-21

  A compound of formula (I): 1 or a salt thereof, or a solvate thereof, wherein Ra represents a group R 5 which is hydrogen, alkyl or optionally substituted aryl and Rb represents a moiety of formula (a): 2 wherein X represents a hydroxy or an alkoxy group wherein the alkyl group may be substituted or unsubstituted or X represents a group NR s R t wherein R s and R t each independently represent hydrogen, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted arylalkyl, an optionally substituted heterocyclic group or an optionally substituted heterocyclylalkyl group, or R s and R t together with the nitrogen to which they are attached form a heterocyclic group; RI represents an alkyl or a substituted or unsubstituted aryl group; and R 2 , R 3 and R 4 each independently represent hydrogen, alkyl, aryl or substituted aryl R 6 and R 7 each independently represents hydrogen, hydroxy, amino, alkoxy, optionally substituted aryloxy, optionally substituted benzyloxy, alkylamino, dialkylamino, halo, trifluoromethyl, trifluoromethoxy, nitro, alkyl, carboxy, carbalkoxy, carbamoyl, alkylcarbamoyl, or R 6 and R 7 together represent methylenedioxy, carbonyldioxy or carbonyldiamino; and R 8 represents hydrogen, hydroxy, alkanoyl, alkyl, aminoalkyl, hydroxyalkyl, carboxyalkyl, carbalkoxyalkyl, carbamoyl or aminosulphonyl; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine

  式（I）的化合物：1或其盐，或其溶剂化物，其中Ra代表一个R5基团，该基团是氢，烷基或可选取代芳基，Rb代表式（a）的一个基团：2其中X代表羟基或烷氧基，其中烷基可能是取代或未取代的，或者X代表羰基-NRsRt，其中Rs和Rt各自独立地代表氢，烷基，取代烷基，可选取代烯基，可选取代芳基，可选取代芳基烷基，可选取代杂环基或可选取代杂环基烷基，或Rs和Rt与它们所连接的氮一起形成杂环基；RI代表烷基或取代或未取代的芳基基团；R2、R3和R4各自独立地代表氢，烷基，芳基或取代芳基；R6和R7各自独立地代表氢，羟基，氨基，烷氧基，可选取代芳氧基，可选取代苯甲氧基，烷基氨基，二烷基氨基，卤素，三氟甲基，三氟甲氧基，硝基，烷基，羧基，羰基氧基，氨基甲酰基，烷基氨甲酰基，或R6和R7一起代表亚甲二氧基，羰基二氧基或羰基二氨基；以及R8代表氢，羟基，烷酰基，烷基，氨基烷基，羟基烷基，羧基烷基，羰基氧基烷基，氨甲酰基或氨基磺酰基；一种制备这样的化合物的方法，包含这样的化合物的制药组合物以及这样的化合物在医学上的用途。
• INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS
  申请人：Smithkline Beecham S.p.A.

  公开号：EP0914321A1

  公开（公告）日：1999-05-12
• Indole Derivatives Useful for Treating Resistance to Antitumor Agents
  申请人：Farina Carlo

  公开号：US20070299084A1

  公开（公告）日：2007-12-27

  The use of a group of indole compounds of formula (I) is described for treating tumours which have developed resistance to antitumour drugs. The compounds of formula (I) can be used in monotherapy, to treat tumours affected by drug resistance, or in co-therapy, as synergistic enhancers of the action of the aforesaid antitumour drugs. In addition, pharmaceutical compositions are described which comprise the indole derivatives of formula (I) in association with antitumour drugs the activity of which is to be enhanced.
• ANTIVIRALS THAT TARGET TRANSPORTERS, CARRIERS, AND ION CHANNELS
  申请人：MELDRUM Eric

  公开号：US20110038852A1

  公开（公告）日：2011-02-17

  This invention provides methods for preventing or treating infection by viruses, in particular an influenza virus by modulating transporters, carriers, and ion channels. Methods to identify, validate, and classify the cellular proteins required by viruses during infection of host cells in order to select agents which can inhibit viral infection are described herein. The method employs a siRNA screening platform and uses gene silencing to map the ‘viral infectome’—a compilation of cellular proteins that the virus needs to establish infection and drive the infectious cycle. Charting the infectome provides information on the viral biology by the identification of host cell proteins involved in viral infection and allows the development of novel anti-viral drugs that prevent the viruses from establishing productive infection in cells.